Videos

Impressive Response Rates for Patients in Migraine Prevention Study: Peter J. Goadsby, MD, PhD, DSc

A. Gordon Smith, MD, FAAN, describes the landscape of investigational therapies for myasthenia gravis, including plasma cells, CAR-T, antigen-specific tolerance.

Peter J. Goadsby, MD, PhD, DSc

Effectiveness of Minimally Invasive Parafascicular Surgery in Intracerebral Hemorrhage: Andrew Russman, DO

The professor of neurology at King’s College, London, spoke about the phase 3 ELEVATE trial investigating atogepant for episodic migraine at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

Andrew Russman, DO

Practice Pearls for Management of NMOSD

The head of the Stroke Program and Medical Director of the Comprehensive Stroke Center at Cleveland Clinic provided perspective on the ENRICH trial, the first positive surgical trial for intracerebral hemorrhage. [WATCH TIME: 5 minutes]

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

Experts in neurology discuss immune tolerance as an alternative strategy and share practice pearls for approaching treatment of NMOSD.

The Unmet Needs in NMOSD

Approaches to NMOSD Treatment in Clinical Practice

Drs Brian Weinshenker, Flavia Nelson, Robert Shin, and Aaron Miller review the unmet needs in the treatment of NMOSD as well as hopes for the future.

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

Unmet Needs in the RRMS Treatment Landscape

Experts in neurology comment on disability and hospitalization rates of NMOSD, as well as how they approach treatment of NMOSD in clinical practice.

Ahmed Zayed Obeidat, MD, PhD;Ravi Dukkipati, MD;Gabriel Pardo, MD, FAAN

Advances in the Management of Relapsing-Remitting Multiple Sclerosis (RRMS)

Ravi Dukkipati, MD, and Gabriel Pardo, MD, FAAN, discuss barriers in accessing treatment for patients with RRMS, as well as a lack of appropriate biomarkers to monitor disease progression.

Ahmed Zayed Obeidat, MD, PhD;Ravi Dukkipati, MD;Gabriel Pardo, MD, FAAN

Clinical Implications of Latest Therapeutic Data for Cognition in MS

Experts in neurology review recent advances in the treatment landscape of relapse-remitting multiple sclerosis (RRMS) and the ever-present challenge of tailoring treatment to individual patients.

Stephen Krieger, MD

Early Progress From the World Brain Study: Imad Najm, MD

Multiple sclerosis expert Stephen Krieger, MD, discusses what can be inferred from the latest data on disease-modifying therapies as it pertains to cognition, and the importance of assessing cognitive performance over time.

Imad Michel Najm, MD

Improving Diagnosis, Screening Patients More Efficiently in Alzheimer Disease: Katherine Turk, MD

The director of Cleveland Clinic’s Epilepsy Center provided an update on the World Brain Study, a large-scale, longitudinal study aimed to observe the early, underlying changes in neurological disorders. [WATCH TIME: 9 minutes]

Katherine Turk, MD

Results of Clinical Trials for CNM-Au8, A Potential ALS Treatment: James Berry, MD, MPH

The behavioral neurologist at VA Boston Healthcare System talked about screening patients for mild cognitive impairment to improve diagnosis in Alzheimer disease at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

James Berry, MD, MPH

Studies With Amantadine-DR/ER for Treatment of Dyskinesia

The director of the Massachusetts General Hospital ALS Care Center talked about CNM-Au8 treatment across three populations, as well as the HEALEY ALS Platform Trial, at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

Amantadine Formulations in Treatment of Dyskinesia in Parkinson Disease

The expert neurology panel discusses clinical trial data of amantadine-DR/ER in treatment of dyskinesia and OFF episodes in Parkinson disease.

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

The Effects of Disease-Modifying Therapy on MS Cognitive Function

Drs William G. Ondo and Rajesh Pahwa analyze the pharmacokinetics of different formulations of amantadine for treatment of dyskinesia in Parkinson disease.

Stephen Krieger, MD

Accuracy of DCTclock to Detect Cognitive Impairment: Ali Jannati, MD, PhD

Stephen Krieger, MD, speaks to the known effects of disease-modifying therapies for multiple sclerosis on cognitive function, among other interventions.

Ali Jannati, MD, PhD

Development of Neuropathology Targeted Treatments in Alzheimer Disease: Madhav R. Thambisetty, MD, PhD

The manager of Clinical Development-Research at Linus Health provided perspective on 2 analyses presented at the 2023 AAN Annual Meeting on the reliability of the DCTclock to detect cognitive impairment. [WATCH TIME: 4 minutes]

Madhav R. Thambisetty, MD, PhD

Preserving Cognitive Status in Pediatric Multiple Sclerosis: Kimberly O’Neill, MD

The senior investigator at the National Institute on Aging talked about targeting pathologies in neurodegenerative diseases at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Kimberly O'Neill, MD

Multiple Sclerosis Journey: Sharing Experiences

The pediatric neuroimmunology fellow at NYU Langone provided perspective on a study presented at AAN 2023 comparing cognitive trajectories of pediatric and adult multiple sclerosis. [WATCH TIME: 3 minutes]

June Halper, MSN, APC-C, MSCN, FAAN;Mary Ann Picone, MD;Gina Murdoch

Multiple Sclerosis Journey: Peer to Peer Support

The panel discusses the value of shared experiences among individuals living with multiple sclerosis.

June Halper, MSN, APC-C, MSCN, FAAN;Mary Ann Picone, MD;Gina Murdoch

Defining and Assessing Cognitive Function in Multiple Sclerosis

Craig Mainor and Gina Murdoch share peer-to-peer support resources for individuals living with multiple sclerosis.

Stephen Krieger, MD

Targeting Neuroinflammation in Huntington Disease: Rajeev Kumar, MD

Stephen Krieger, MD, discusses how cognition is defined in multiple sclerosis and the tools to evaluate patients' cognitive performance.

Rajeev Kumar, MD

April 23rd 2023

Associations Between Organ Health and Brain Function, Preserving Brain Health: Costantino Iadecola, MD

The medical director of the Rocky Mountain Movement Disorders Center talked about the motivations of the phase 2 study on ANX005 for Huntington disease at the 2023 AAN Annual Meeting. [WATCH TIME: 3 minutes]

Costantino Iadecola, MD

April 23rd 2023

Using Artificial Intelligence Applications in Neurology to the Field: Kathryn A. Davis, MD, MSc

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine spoke about preserving brain function through medical, sociopolitical, and educational efforts as part of his presentation at the 2023 AAN annual meeting. [WATCH TIME: 6 minutes]

Kathryn A. Davis, MD, FAES

April 22nd 2023

Targeting Blood Vessels to Improve Treatment for Alzheimer Disease: Costantino Iadecola, MD

The associate professor of neurology and director of the Penn Epilepsy Center at the University of Pennsylvania talked about the potential of using artificial intelligence in the field of neurology as part of an upcoming session at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]

Costantino Iadecola, MD

April 22nd 2023

DEA Rules Fenfluramine No Longer Controlled Substance, Positive FDA ADComm Meeting of Brexpiprazole, Antiamyloid Drugs Accelerate Brain Atrophy

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine talked about the importance of vascular health in preventing cognitive impairment as part of his presentation at the 2023 AAN annual meeting. [WATCH TIME: 6 minutes]

NeurologyLive® Staff

April 22nd 2023

Expanding KP1077’s Clinical Program to Address Narcolepsy and Other Conditions: Christal Mickle

Neurology News Network for the week ending April 22, 2023. [WATCH TIME: 4 minutes]

Christal Mickle

April 21st 2023

Advances in Neurology, Contributions to Brain Health: Costantino Iadecola, MD

The cofounder and chief product development officer of Zevra Therapeutics talked about the phase 1 clinical trial of KP1077 for narcolepsy and potentially using it to treat other conditions. [WATCH TIME: 5 minutes]

Costantino Iadecola, MD

April 20th 2023